NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its fourth-quarter revenues dropped 4 percent year over year, while issuing a separate statement once again rejecting Roche's offer to acquire the company for $44.50 per share, or $5.7 billion.